FAQ

Wegovy is a prescription medication containing semaglutide, a glucagon-like peptide-1 receptor agonist commonly called a GLP-1 medication. In the United States, Wegovy is approved for long-term weight reduction in certain adults with obesity or overweight. Wegovy injection is also approved for adolescents aged 12 and older with obesity. Some Wegovy formulations have additional approved uses, including reducing major cardiovascular risks in certain adults and treating specific adults with MASH and liver fibrosis.

Wegovy activates GLP-1 receptors involved in appetite and calorie intake. It can reduce hunger, help people feel satisfied with less food, and support weight loss when used together with a reduced-calorie diet and increased physical activity. Semaglutide does not simply “burn fat.” Its effects on body weight are mainly connected to reduced calorie intake and changes in appetite regulation.

Wegovy and Ozempic both contain semaglutide, but they are separate prescription products with different approved uses, strengths, and treatment instructions. Wegovy is primarily associated with chronic weight management, while Ozempic has traditionally been prescribed for adults with type 2 diabetes and certain related health risks. They should not be treated as interchangeable without guidance from a licensed healthcare professional.

In the United States, Wegovy is available in both injectable and tablet forms. Wegovy injection is generally administered once weekly, while Wegovy tablets are taken once daily under specific administration instructions. Available formulations and approved uses may differ between countries, so patients should follow the product information and prescription provided in their location.

Wegovy may be prescribed for adults with obesity or adults with overweight who also have at least one weight-related medical condition. The injectable form is also approved for adolescents aged 12 years and older with obesity. Eligibility is not based on appearance or a desire to lose a small amount of weight. A licensed healthcare professional should evaluate medical history, body mass index, current medications, possible contraindications, and the potential benefits and risks.

Results vary considerably. In a major 68-week clinical study, adults receiving the 2.4 mg weekly Wegovy injection lost an estimated average of 14.9% of their starting body weight, compared with 2.4% among those receiving placebo. Other Wegovy formulations, doses, study populations, and treatment periods have produced different averages. Clinical trial results describe groups of participants. They do not guarantee that an individual person will lose the same amount.

Results may be influenced by starting weight, treatment duration, tolerability, medical conditions, other medications, diet, physical activity, treatment interruptions, and whether someone can remain on the prescribed treatment plan. A dramatic online transformation does not represent the experience of every Wegovy user. Some people report substantial weight loss, while others lose less, stop because of side effects, or do not find the treatment suitable.

Commonly reported side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, acid reflux, and hair loss. Not everyone experiences the same symptoms or severity. Side effects that are persistent, worsening, or difficult to manage should be discussed with a healthcare professional.

Yes. Although many reported effects are gastrointestinal, Wegovy also carries warnings for potentially serious problems. These include pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications in some people with type 2 diabetes, increased heart rate, and pulmonary aspiration during procedures involving anesthesia or deep sedation. Wegovy also has a boxed warning concerning thyroid C-cell tumors observed in rodents. It is unknown whether Wegovy causes medullary thyroid carcinoma in humans. The medication is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Wegovy should not be used for weight reduction during pregnancy. The prescribing information advises discontinuing it when pregnancy is recognized for patients using it for weight or cardiovascular risk reduction. Because semaglutide remains in the body for an extended period, the label also advises discontinuing Wegovy at least two months before a planned pregnancy. Anyone who is pregnant, planning a pregnancy, or becomes pregnant during treatment should contact a healthcare professional.

Missed-dose directions differ between Wegovy injection and Wegovy tablets and may also depend on how much time has passed. Check the Medication Guide supplied with the prescription or contact a pharmacist or prescriber. Do not take additional medication or create a new schedule based only on advice from reviews, forums, or social media.

An overdose involving a GLP-1 medication may cause severe nausea, vomiting, or low blood sugar and may require prolonged observation because semaglutide has a long half-life. In the United States, contact Poison Help at 1-800-222-1222 or seek immediate medical assistance. Call 911 when symptoms appear severe or life-threatening. Do not wait for an online reply or attempt to correct a dosing mistake by taking another dose.

Appetite may increase again, and weight regain is common, although individual experiences vary. In an extension of the STEP 1 trial, participants regained an average of approximately two-thirds of the weight they had previously lost during the year after semaglutide and structured lifestyle support were discontinued. This does not mean every person will regain the same amount. Decisions about continuing, reducing, switching, or stopping treatment should be discussed with a healthcare professional.

The amount someone pays can depend on the Wegovy formulation and strength, insurance coverage, prior-authorization requirements, pharmacy pricing, location, and eligibility for savings or assistance programs. Advertised savings prices may have eligibility restrictions and can change. Patients should confirm the current cost directly with their insurer, pharmacy, or the official assistance program rather than relying on an old review or social media post.

Wegovy reviews can help readers understand what individual people report about weight loss, side effects, cost, insurance, availability, and daily treatment challenges. However, a review is a personal experience—not clinical evidence. A positive review cannot guarantee similar results, and a negative review cannot predict that another person will experience the same problem. Reviews are most useful when they are read alongside reliable medical information and discussed with a licensed healthcare professional.

Visitors may submit a review describing their own Wegovy experience. Reviews should be honest, relevant, and based on personal experience. They should not contain advertising, dangerous medical instructions, harassment, private identifying information, or claims written on behalf of a manufacturer, clinic, pharmacy, seller, or marketing agency.

Wegovy.review may moderate submissions for spam, promotional content, abuse, or material that violates site policies. However, the website cannot independently confirm every reviewer’s identity, prescription history, diagnosis, weight change, or reported side effects. Publication does not mean that every medical statement in a review has been verified.

No. Reviews may offer perspective, but they cannot determine whether Wegovy is appropriate for a specific person, explain the cause of a symptom, or provide a safe personalized treatment plan. Questions about eligibility, side effects, dosing, missed medication, interactions, pregnancy, overdose, or stopping treatment should be directed to a licensed healthcare professional.

No. Wegovy.review does not manufacture, prescribe, dispense, sell, or deliver Wegovy, semaglutide, compounded medication, or any other drug product. The website provides independent educational content and user-submitted experiences.

No. Wegovy.review is an independent educational and review platform. It is not affiliated with, sponsored by, endorsed by, or connected with Novo Nordisk A/S. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Product names are used for identification, commentary, comparison, review, and educational discussion only.